/TLX
TLX Stock - Telix Pharmaceuticals Limited
Healthcare|BiotechnologyNASDAQ
$7.80-0.13%
$0.01 (-0.13%) • Dec 19
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.71
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+137.2%upside
Target: $18.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TLX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.72 – $7.88
TARGET (TP)$18.50
STOP LOSS$7.18
RISK/REWARD1:17.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.22
52W High$30.36
52W Low$7.72
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $783.21M | $502.55M | $160.10M | $7.60M | $5.21M |
| Gross Profit | $509.68M | $314.39M | $29.34M | $-29,765,000 | $-16,877,000 |
| Gross Margin | 65.1% | 62.6% | 18.3% | -391.9% | -323.7% |
| Operating Income | $82.13M | $51.89M | $-91,930,000 | $-81,247,000 | $-49,253,000 |
| Net Income | $49.92M | $5.21M | $-104,079,000 | $-80,510,000 | $-44,887,000 |
| Net Margin | 6.4% | 1.0% | -65.0% | -1059.9% | -861.1% |
| EPS | $0.15 | $0.02 | $-0.34 | $-0.29 | $-0.17 |
Company Overview
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
80%
Hold / Neutral
1
20%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish1 Neutral/Bearish
Price Targets
$22
Average Target
↑ 182.1% Upside
Now
$21
Low
$22
Average
$23
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 18th 2025 | Citigroup | Initiation | Buy | $22 |
| August 28th 2025 | JP Morgan | Downgrade | Neutral | - |
| July 3rd 2025 | H.C. Wainwright | Initiation | Buy | $23 |
| June 5th 2025 | Wedbush | Initiation | Outperform | $22 |
| November 15th 2024 | UBS | Initiation | Buy | $21 |
Earnings History & Surprises
TLXBeat Rate
37%
Last 19 quarters
Avg Surprise
-7.9%
EPS vs Estimate
Beats / Misses
7/12
Last 12 quarters
Latest EPS
$-0.01
Q3 2025
EPS Surprise History
Q2 18
+13.8%
$-0.60vs$-0.70
Q3 18
-19.2%
$-1.76vs$-1.48
Q4 18
-35.8%
$-0.25vs$-0.18
Q1 19
-56.1%
$-0.20vs$-0.13
Q2 19
-11.9%
$0.02vs$0.02
Q3 19
+20.0%
$0.01vs$0.01
Q4 19
-11.0%
$-0.10vs$-0.09
Q3 25
+95.1%
$-0.01vs$-0.14
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 18, 2026 | — | — | — | — |
Q3 2025 | Aug 20, 2025 | $-0.14 | $-0.01 | +95.1% | ✓ BEAT |
Q4 2019 | Dec 31, 2019 | $-0.09 | $-0.10 | -11.0% | ✗ MISS |
Q3 2019 | Sep 30, 2019 | $0.01 | $0.01 | +20.0% | ✓ BEAT |
Q2 2019 | Jun 30, 2019 | $0.02 | $0.02 | -11.9% | ✗ MISS |
Q1 2019 | Mar 31, 2019 | $-0.13 | $-0.20 | -56.1% | ✗ MISS |
Q4 2018 | Dec 31, 2018 | $-0.18 | $-0.25 | -35.8% | ✗ MISS |
Q3 2018 | Sep 30, 2018 | $-1.48 | $-1.76 | -19.2% | ✗ MISS |
Q2 2018 | Jun 30, 2018 | $-0.70 | $-0.60 | +13.8% | ✓ BEAT |
Q1 2018 | Mar 31, 2018 | $0.05 | $0.04 | -27.9% | ✗ MISS |
Q4 2017 | Dec 31, 2017 | $-1.53 | $-1.59 | -4.2% | ✗ MISS |
Q3 2017 | Sep 30, 2017 | $0.91 | $0.66 | -27.1% | ✗ MISS |
Q2 2017 | Jun 30, 2017 | $0.00 | $0.00 | +7.4% | ✓ BEAT |
Q1 2017 | Mar 31, 2017 | $-0.39 | $-0.73 | -87.1% | ✗ MISS |
Q4 2016 | Dec 31, 2016 | $0.22 | $0.17 | -25.8% | ✗ MISS |
Q3 2016 | Sep 30, 2016 | $0.06 | $0.08 | +27.9% | ✓ BEAT |
Q2 2016 | Jun 30, 2016 | $0.04 | $0.05 | +30.3% | ✓ BEAT |
Q1 2016 | Mar 31, 2016 | $-0.65 | $-0.65 | +0.1% | ✓ BEAT |
Q4 2015 | Dec 31, 2015 | $-0.36 | $-0.39 | -8.0% | ✗ MISS |
Q3 2015 | Sep 30, 2015 | $0.15 | $0.10 | -29.9% | ✗ MISS |
Latest News
Telix Pharma Collaborates With Varian To Develop Clinical Applications That Combine Telix's Theranostic Products And External Beam Radiation Therapy
📈 PositiveBenzinga•Dec 10, 2025, 12:04 PM•Also:
Telix Pharma's ZIRCON-X Study Shows TLX250-CDx Imaging Could Alter Clinical Management In Nearly Half of Patients
📈 PositiveBenzinga•Nov 19, 2025, 07:03 PM•Also:
Telix's TLX250-CDx Included In Global Nuclear Medicine Guidelines For Renal Imaging
📈 PositiveBenzinga•Oct 23, 2025, 11:11 AM•Also:
Telix Pharmaceuticals Doses First Patient In Phase 1 Clinical Trial Of TLX090
📈 PositiveBenzinga•Oct 22, 2025, 08:03 PM•Also:
Telix Pharmaceuticals shares are trading higher. The company, yesterday, reported a year-over-year increase in Q3 revenue results and raised its FY25 revenue guidance.
📈 PositiveBenzinga•Oct 15, 2025, 01:03 PM•Also:
Telix Pharmaceuticals Sees Q3 Sales $206.000M
📈 PositiveBenzinga•Oct 14, 2025, 07:21 AM•Also:
Telix Pharmaceuticals Raises FY2025 Sales Guidance from $770.000M-$800.000M to $800.000M-$820.000M
📈 PositiveBenzinga•Oct 14, 2025, 07:21 AM•Also:
Telix Reports Q3 Revenue Of $206M Up 53% Year Over Year, Raises FY 2025 Guidance To $800M–$820M
📈 PositiveBenzinga•Oct 14, 2025, 06:31 AM•Also:
CORRECTION: UBS Analyst David Dai Maintained Buy Rating On Telix Pharmaceuticals And Lowered PT From $23 To $20
➖ NeutralBenzinga•Sep 24, 2025, 01:41 PM•Also:
Telix Pharmaceuticals shares are trading higher after the United States Centers for Medicare & Medicaid Services granted the company Transitional Pass-Through payment status for Gozellix.
📈 PositiveBenzinga•Sep 23, 2025, 03:34 PM•Also:
US Centers For Medicare & Medicaid Services Grants Transitional Pass-Through Payment Status To Telix's Gozellix PSMA-PET Imaging Agent For Prostate Cancer
📈 PositiveBenzinga•Sep 23, 2025, 02:17 PM•Also:
UBS Maintains Buy on Telix Pharmaceuticals, Lowers Price Target to $20
📈 PositiveBenzinga•Sep 23, 2025, 01:52 PM•Also:
Citigroup Initiates Coverage On Telix Pharmaceuticals with Buy Rating, Announces Price Target of $22
📈 PositiveBenzinga•Sep 18, 2025, 03:21 PM•Also: ,
HC Wainwright & Co. Maintains Buy on Telix Pharmaceuticals, Lowers Price Target to $20
➖ NeutralBenzinga•Sep 10, 2025, 02:29 PM•Also:
Reported Earlier, Telix Initiates Phase 3 BiPASS Trial In Australia And US To Advance PSMA-PET Imaging For Prostate Cancer Diagnosis
📈 PositiveBenzinga•Sep 10, 2025, 07:38 AM•Also:
Telix Pharmaceuticals shares are trading lower after JPMorgan on Thursday downgraded the stock from Overweight to Neutral.
📉 NegativeBenzinga•Aug 29, 2025, 05:57 PM•Also:
JP Morgan Downgrades Telix Pharmaceuticals to Neutral
➖ NeutralBenzinga•Aug 28, 2025, 08:09 PM•Also: ,
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target
📈 PositiveBenzinga•Aug 28, 2025, 01:12 PM•Also:
Telix Pharmaceuticals stock drops as SEC probes disclosures tied to cancer treatment
📉 NegativeSeeking Alpha•Jul 23, 2025, 09:12 AM•Also:
Frequently Asked Questions about TLX
What is TLX's current stock price?
Telix Pharmaceuticals Limited (TLX) is currently trading at $7.80 per share. The stock has moved -0.13% today.
What is the analyst price target for TLX?
The average analyst price target for TLX is $18.50, based on 1 analyst.
What sector is Telix Pharmaceuticals Limited in?
Telix Pharmaceuticals Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TLX's market cap?
Telix Pharmaceuticals Limited has a market capitalization of $2.64 billion, making it a mid-cap company.
Does TLX pay dividends?
No, Telix Pharmaceuticals Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACAD
ACADIA Pharmaceuticals Inc.
$27.16
Mkt Cap: $4.6B
ADMA
ADMA Biologics, Inc.
$19.58
Mkt Cap: $4.7B
BLTE
Belite Bio, Inc
$156.00
Mkt Cap: $5.4B
CELC
Celcuity Inc.
$101.16
Mkt Cap: $4.7B
DYN
Dyne Therapeutics, Inc.
$19.85
Mkt Cap: $2.8B
LGND
Ligand Pharmaceuticals Incorporated
$200.33
Mkt Cap: $3.9B
MIRM
Mirum Pharmaceuticals, Inc.
$77.74
Mkt Cap: $3.8B
PRAX
Praxis Precision Medicines, Inc.
$272.92
Mkt Cap: $5.8B
RARE
Ultragenyx Pharmaceutical Inc.
$33.50
Mkt Cap: $3.2B
SLNO
Soleno Therapeutics, Inc.
$47.85
Mkt Cap: $2.6B
Explore stocks similar to TLX for comparison